Skip to content

Study · Non-randomized trial · 2018

13 results

Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.

Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C

Medicine1 Nov 2018Cited by 10 (Europe PMC)

PMID30461654 (opens in a new tab)PMCIDPMC6392772 (opens in a new tab)DOI10.1097/md.0000000000013341 (opens in a new tab)PepBankPUB-30461654
Read at sourcePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, rhPTH (1-34) increased lumbar spine BMD at week 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased lower spine bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The rhPTH (1-34) increased BMD of lumbar spine (1-4), but decreased BMD of femoral neck and total hip at week 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, rhPTH (1-34) decreased femoral neck BMD at week 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) decreased femoral neck bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFemoral neck BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The rhPTH (1-34) increased BMD of lumbar spine (1-4), but decreased BMD of femoral neck and total hip at week 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with osteoporosis, rhPTH (1-34) decreased total hip BMD at week 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) decreased total hip bone density compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The rhPTH (1-34) increased BMD of lumbar spine (1-4), but decreased BMD of femoral neck and total hip at week 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased PINP above baseline at weeks 24 and 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased PINP compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In PTH group, serum levels of PINP, ALP, and β-CTX were significantly elevated above baseline at week 24 and 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased ALP above baseline at weeks 24 and 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased alkaline phosphatase compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAlkaline phosphatase
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In PTH group, serum levels of PINP, ALP, and β-CTX were significantly elevated above baseline at week 24 and 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased β-CTX above baseline at weeks 24 and 48.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased β-CTX compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Increaseβ-CTX
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In PTH group, serum levels of PINP, ALP, and β-CTX were significantly elevated above baseline at week 24 and 48 after treatment.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) significantly decreased PDGF-BB levels.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) decreased PDGF-BB levels.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePDGF-BB
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) and ALN significantly decreased levels of PDGF-BB, but not levels of VEGF.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) did not significantly decrease VEGF levels.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) did not significantly decrease VEGF levels.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVEGF
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) and ALN significantly decreased levels of PDGF-BB, but not levels of VEGF.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  9. 09HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased serum calcium.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased blood calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum calcium
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  10. 10HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased serum phosphorus.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased blood phosphorus.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum phosphorus
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  11. 11HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) increased triglyceride levels.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) increased triglyceride levels.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTriglyceride
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  12. 12HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis, rhPTH (1-34) decreased total cholesterol.

    In plain wordsIn women with osteoporosis, rhPTH (1-34) decreased total cholesterol.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) increased levels of calcium, phosphorus and triglyceride, but decreased levels of total cholesterol.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.
  13. 13HumanNon-randomized trialSafety outcome

    The study reported rhPTH (1-34) as safe in postmenopausal women with osteoporosis without specific event counts.

    In plain wordsThe study reported rhPTH (1-34) as safe in women with osteoporosis, without specific event counts.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableGeneral safety
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    rhPTH (1-34) and ALN were safe in the treatment of postmenopausal osteoporosis.
    1 context sentence
    Summary · context
    PTH group received daily subcutaneous injection of rhPTH (1-34), and ALN group were treated orally with ALN per week.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.